Pfizer posted results for fiscal 2025 that were mixed. Q2 revenue was $14.65 billion, beating expectations, with net income of $2.91 billion and diluted earnings per share of $0.78. For the 3rd quarter, revenue was $16.65 billion, net income was $3.54 billion, and diluted earnings per share were $0.87. For the 4th quarter, it reported revenue of $17.56 billion, but net income of -$1.65 billion and adjusted earnings per share of $0.66. According to estimates, full-year sales will reach 61 to 64 billion USD and adjusted earnings per share 2.9 to 3.15 USD. Pfizer confirmed about $7.2 billion in cost savings through 2027 and returned $9.8 billion in dividends to shareholders. The company is focusing on newly acquired assets from Metsera focused on anti-obesity drugs.[1][2][3][4][6]